Literature DB >> 21553115

A single plasmid transfection that offers a significant advantage associated with puromycin selection, fluorescence-assisted cell sorting, and doxycycline-inducible protein expression in mammalian cells.

Takayuki Iwaki1, Kazuo Umemura.   

Abstract

Although there are several inducible expression systems for mammalian cells, the most reliable one is the tetracycline-regulated expression system. This system is well-established and widely used by many researchers. Although Clontech provides several types of cells that stably express reverse tetracycline transactivator (rtTA), the cells that are not provided can be generated with pTet-On-Advanced by first integrating this plasmid into the require type of cell and then introducing the genes of interest. These processes are experimental bottlenecks. To improve this situation, we synthesized an all-in-one vector, termed pMAK17, which enables constitutive expression of puromycin N-acetyltransferase, modified Discosoma red fluorescent protein, and rtTA, as well as P(Tight)-driven enhanced green fluorescent protein (EGFP). The pMAK17-transfected cells could be successfully induced to express EGFP, were selectable by fluorescence-activated cell sorting, and displayed puromycin resistance.

Entities:  

Year:  2011        PMID: 21553115      PMCID: PMC3140840          DOI: 10.1007/s10616-011-9357-6

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  5 in total

1.  Rapid selection of Drosophila S2 cells with the puromycin resistance gene.

Authors:  Takayuki Iwaki; Mariana Figuera; Victoria A Ploplis; Francis J Castellino
Journal:  Biotechniques       Date:  2003-09       Impact factor: 1.993

2.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

3.  pac gene as efficient dominant marker and reporter gene in mammalian cells.

Authors:  S de la Luna; J Ortín
Journal:  Methods Enzymol       Date:  1992       Impact factor: 1.600

4.  A single plasmid transfection that offers a significant advantage associated with puromycin selection in Drosophila Schneider S2 cells expressing heterologous proteins.

Authors:  Takayuki Iwaki; Francis J Castellino
Journal:  Cytotechnology       Date:  2008-02-08       Impact factor: 2.058

5.  Biosynthesis of puromycin by Streptomyces alboniger: characterization of puromycin N-acetyltransferase.

Authors:  J Vara; J A Perez-Gonzalez; A Jimenez
Journal:  Biochemistry       Date:  1985-12-31       Impact factor: 3.162

  5 in total
  3 in total

1.  Identification and characterization of a drug-sensitive strain enables puromycin-based translational assays in Saccharomyces cerevisiae.

Authors:  Gregory A Cary; Sung Hwan Yoon; Cecilia Garmendia Torres; Kathie Wang; Michelle Hays; Catherine Ludlow; David R Goodlett; Aimée M Dudley
Journal:  Yeast       Date:  2014-03-19       Impact factor: 3.239

2.  DRAM1 regulates apoptosis through increasing protein levels and lysosomal localization of BAX.

Authors:  J-J Guan; X-D Zhang; W Sun; L Qi; J-C Wu; Z-H Qin
Journal:  Cell Death Dis       Date:  2015-01-29       Impact factor: 8.469

3.  Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies.

Authors:  Charli E Harlow; Josan Gandawijaya; Rosemary A Bamford; Emily-Rose Martin; Andrew R Wood; Peter J van der Most; Toshiko Tanaka; Hampton L Leonard; Amy S Etheridge; Federico Innocenti; Robin N Beaumont; Jessica Tyrrell; Mike A Nalls; Eleanor M Simonsick; Pranav S Garimella; Eric J Shiroma; Niek Verweij; Peter van der Meer; Ron T Gansevoort; Harold Snieder; Paul J Gallins; Dereje D Jima; Fred Wright; Yi-Hui Zhou; Luigi Ferrucci; Stefania Bandinelli; Dena G Hernandez; Pim van der Harst; Vickas V Patel; Dawn M Waterworth; Audrey Y Chu; Asami Oguro-Ando; Timothy M Frayling
Journal:  Am J Hum Genet       Date:  2022-09-01       Impact factor: 11.043

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.